London, UK, 13 August 2019 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, is pleased to announce that in vitro data published […]
Presentations And Publications
Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of invasive fungal lung infections, announces the publication of data demonstrating the synergistic antifungal effect of combining topical administration […]
02 July 2019
A recent publication in Drug Discovery Today by pulmocide scientists provides an in depth review on current approaches to the discovery of new treatments which are administered by the inhaled […]
29 May 2018